I

Integer Holdings Corporation

Medical device CDMO for cardiac devices

New Product Introduction Quality Engineer 3

Full-TimeUpdated on 10/21/2026
$95.7k - $125k+ Cash-based incentive program + 401(k) match
Senior
Bachelor's, Master's
Brooklyn Park, MN, USA
In Person
Manufacturing Quality & TestQuality Engineering

About the job

Requirements
  • A bachelor’s degree in engineering or a related field is required; a master’s degree may also be held.
  • At least 5 years of progressive engineering and/or technically focused experience is required. Candidates who do not meet the education requirement may be considered with 10+ years of relevant experience.
  • A strong technical and problem-solving foundation is required; training and certifications in problem-solving and project-management methodologies are preferred, including Six Sigma Green Belt at minimum and Black Belt preferred.
  • Awareness of relevant domestic and international regulations and industry standards, such as ISO, QSR, UL, MDD, and TGA.
  • Good knowledge of Microsoft Office.
  • Strong working knowledge of statistics and use of Minitab; must be considered a subject matter expert in statistics.
  • Competence in written and oral communication; candidates outside the United States must demonstrate written and oral English communication skills.
  • Ability to contribute effectively to a team or produce technical results individually.
Responsibilities
  • Apply engineering principles and practices to New Product Introduction projects and ensure customer expectations are met or exceeded by evaluating procedures that support production of quality products.
  • Develop approaches to complex problems, advance technology, apply engineering concepts to resolve acute or chronic problems, and conduct process or measurement-system capability studies.
  • Provide management with technical guidance as required, develop documentation for process improvement and project implementation, and act independently on technical matters within the role’s field.
  • Adhere to Integer’s values and applicable safety, environmental, security, quality, FDA, company, operating-procedure, and other regulatory requirements.
  • Support regulatory and agency inspections, audits, investigations, and inquiries concerning control and assessment of product design and manufacturing quality.
  • Develop new test methods, including designing and manufacturing tooling, fixtures, and templates; test and validate methods, including gauge repeatability and reproducibility studies and statistical analysis using software such as Minitab.
  • Update test-method procedures and process standard operating procedures; provide technical input to root-cause analysis, prepare investigation reports within key performance indicator metrics and timelines, and participate in cross-functional New Product Introduction reviews.
  • Review procedures, protocols, reports, and related documents for test-method development, process testing, and process validation associated with New Product Introduction.
  • Lead cross-functional project teams supporting New Product Introduction, provide technical expertise, participate in the product development process, and ensure compliance throughout that process.
  • Support planning and execution of risk-management activities under ISO 14971; periodically review internal and external standards and identify gaps requiring action.
  • Lead continuous-improvement projects, assist with product transfers, and perform technical projects to investigate product and process improvement opportunities using Integer’s quality-management and production methodologies.
  • Lead generation and completion of test-method validation protocols and reports; work with Manufacturing Engineers to review new-product processes, coordinate process validations and capability studies, and recommend process-monitoring devices where applicable.
  • Develop inspection techniques and procedures to ensure product integrity against design specifications; write, approve, and implement incoming, in-process, and final inspection procedures.
  • Ensure non-conforming material dispositions follow applicable procedures and corrective actions are adequate to prevent recurrence.
  • Participate in plant corrective and preventive action activities, including analysis of complaint, supplier-quality, non-conforming-material, training-effectiveness, and root-cause data and trends.
  • Apply standard data-analysis practices and observe products and processes to establish root causes of failures or justify product and process improvements.
  • Support internal quality-audit activities as applicable; uphold the Quality Management System, support corrective and preventive action investigation and implementation, and contribute to quality key performance indicators and the journey to 5 Sigma.
  • Support manufacturing-excellence and market-focused innovation strategies through site Hoshin plans, quality plans, validation master plans, quality-improvement initiatives, and updates to quality/regulatory weekly and monthly metrics.
  • Support sustained change by ensuring customer change notifications are initiated and completed and by supporting continuous-improvement activities.
  • Support standardization through workplace organization and visual controls (5S), manufacturing standard work, and training and certification programs where applicable.
  • Promote associate engagement through standardized problem-solving methods, behavior-based safety programs, and improvement-idea and suggestion systems; support systems and process optimization through built-in-quality principles.
  • Support Integer Environmental, Health and Safety programs, adhere to Integer’s values, achieve defined goals and project milestones, and generate and support implementation of continuous-improvement suggestions.
  • Perform other duties as needed and directed by line supervision.
Desired Qualifications
  • Six Sigma training and certifications, with Green Belt as a minimum and Black Belt preferred.

About the company

I

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $464.1 million, beating estimates despite weak medtech demand.
  • Integer expects demand recovery after New Ross's July 27-August 10, 2026 shutdown.
  • KKR plans new capacity, technology, and employee ownership after closing by year-end 2026.

What critics are saying

  • Integer withdrew 2026 guidance on August 3, 2026, after KKR announced the buyout.
  • Schall, Brown & Schwartz opened an August 23, 2026 fiduciary-duty investigation.
  • Regulatory or stockholder rejection kills the KKR deal and leaves Integer's weak standalone outlook exposed.

What makes Integer Holdings Corporation unique

  • Integer's R&D Velocity integrates design, prototyping, and manufacturing for complex medtech programs.
  • Its 33-facility global network spans electrophysiology, neuromodulation, and structural heart.
  • KKR's August 3, 2026, $5.7 billion bid validates Integer's scale and customer lock-in.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Adoption Assistance
  • Parental Leave
  • 401(k) Company Match
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-1%
Ticker Report
Aug 29th, 2026
Boussard & Gavaudan Gestion Sas Makes New $2.60 Million Investment in Integer Holdings Corporation $ITGR

Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]

Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 4th, 2026
Integer Holdings acquired by KKR for $5.7B in all-cash deal at $127 per share

Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.

BizWire Express
Aug 3rd, 2026
KKR to acquire Integer for $5.7B in all-cash deal at $127 per share

KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.

Yahoo Finance
Aug 3rd, 2026
Integer Holdings beats Q2 expectations with $464M revenue and $1.60 earnings per share

Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.